GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (OTCPK:TDSGF) » Definitions » 3-Year Dividend Growth Rate

Telo Genomics (Telo Genomics) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Telo Genomics 3-Year Dividend Growth Rate?

Telo Genomics's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

The historical rank and industry rank for Telo Genomics's 3-Year Dividend Growth Rate or its related term are showing as below:

TDSGF's 3-Year Dividend Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 9.25
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Telo Genomics's Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00. As of today, Telo Genomics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Telo Genomics's 3-Year Dividend Growth Rate

For the Diagnostics & Research subindustry, Telo Genomics's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Telo Genomics's 3-Year Dividend Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Telo Genomics's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Telo Genomics's 3-Year Dividend Growth Rate falls into.


Telo Genomics 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Telo Genomics  (OTCPK:TDSGF) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Telo Genomics's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2023 )/ EPS without NRI (Q: Dec. 2023 )
=0/ -0.007
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telo Genomics 3-Year Dividend Growth Rate Related Terms>

Telo Genomics (Telo Genomics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (OTCPK:TDSGF) » Definitions » 3-Year Dividend Growth Rate
Comparable Companies
XCNQ:SONA TSXV:AVCR XCNQ:IZO XCNQ:BUX TSXV:ARC TSX:SZLS TSXV:JUMP XCNQ:VTAL NEOE:MEDV TSXV:MBI.H TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN
Traded in Other Exchanges
3D0A:Germany TELO:Canada
Address
101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7
Website
https://www.telodx.com
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in the development and commercialization of diagnostic and prognostic products. The company is developing diagnostic and prognostic products for cancer and neurological disorders.